392 related articles for article (PubMed ID: 17327887)
1. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.
van Haren NE; Hulshoff Pol HE; Schnack HG; Cahn W; Mandl RC; Collins DL; Evans AC; Kahn RS
Neuropsychopharmacology; 2007 Oct; 32(10):2057-66. PubMed ID: 17327887
[TBL] [Abstract][Full Text] [Related]
2. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment.
McClure RK; Phillips I; Jazayerli R; Barnett A; Coppola R; Weinberger DR
Psychiatry Res; 2006 Dec; 148(2-3):121-32. PubMed ID: 17097276
[TBL] [Abstract][Full Text] [Related]
3. Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment.
McClure RK; Carew K; Greeter S; Maushauer E; Steen G; Weinberger DR
Schizophr Res; 2008 Jan; 98(1-3):29-39. PubMed ID: 17976957
[TBL] [Abstract][Full Text] [Related]
4. A follow-up MRI study of the fusiform gyrus and middle and inferior temporal gyri in schizophrenia spectrum.
Takahashi T; Zhou SY; Nakamura K; Tanino R; Furuichi A; Kido M; Kawasaki Y; Noguchi K; Seto H; Kurachi M; Suzuki M
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1957-64. PubMed ID: 21820482
[TBL] [Abstract][Full Text] [Related]
5. Brain morphometry of individuals with schizophrenia with and without antipsychotic medication – The Northern Finland Birth Cohort 1966 Study.
Moilanen J; Huhtaniska S; Haapea M; Jääskeläinen E; Veijola J; Isohanni M; Koponen H; Miettunen J
Eur Psychiatry; 2015 Jul; 30(5):598-605. PubMed ID: 25791180
[TBL] [Abstract][Full Text] [Related]
6. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study.
Lui S; Deng W; Huang X; Jiang L; Ma X; Chen H; Zhang T; Li X; Li D; Zou L; Tang H; Zhou XJ; Mechelli A; Collier DA; Sweeney JA; Li T; Gong Q
Am J Psychiatry; 2009 Feb; 166(2):196-205. PubMed ID: 18981063
[TBL] [Abstract][Full Text] [Related]
7. Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia.
Tomelleri L; Jogia J; Perlini C; Bellani M; Ferro A; Rambaldelli G; Tansella M; Frangou S; Brambilla P;
Eur Neuropsychopharmacol; 2009 Dec; 19(12):835-40. PubMed ID: 19717283
[TBL] [Abstract][Full Text] [Related]
8. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study.
Whitford TJ; Grieve SM; Farrow TF; Gomes L; Brennan J; Harris AW; Gordon E; Williams LM
Am J Psychiatry; 2007 Jul; 164(7):1082-9. PubMed ID: 17606660
[TBL] [Abstract][Full Text] [Related]
9. Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM.
Mané A; Falcon C; Mateos JJ; Fernandez-Egea E; Horga G; Lomeña F; Bargalló N; Prats-Galino A; Bernardo M; Parellada E
Schizophr Res; 2009 Oct; 114(1-3):136-43. PubMed ID: 19683418
[TBL] [Abstract][Full Text] [Related]
10. Gray matter volume changes following antipsychotic therapy in first-episode schizophrenia patients: A longitudinal voxel-based morphometric study.
Guo F; Zhu YQ; Li C; Wang XR; Wang HN; Liu WM; Wang LX; Tian P; Kang XW; Cui LB; Xi YB; Yin H
J Psychiatr Res; 2019 Sep; 116():126-132. PubMed ID: 31233895
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic drug effects on brain morphology in first-episode psychosis.
Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
[TBL] [Abstract][Full Text] [Related]
12. Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study.
Stip E; Mancini-Marïe A; Letourneau G; Fahim C; Mensour B; Crivello F; Dollfus S
Int Clin Psychopharmacol; 2009 Jan; 24(1):34-41. PubMed ID: 19077676
[TBL] [Abstract][Full Text] [Related]
13. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia.
Boonstra G; van Haren NE; Schnack HG; Cahn W; Burger H; Boersma M; de Kroon B; Grobbee DE; Hulshoff Pol HE; Kahn RS
J Clin Psychopharmacol; 2011 Apr; 31(2):146-53. PubMed ID: 21346618
[TBL] [Abstract][Full Text] [Related]
14. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Takahashi T; Wood SJ; Yung AR; Soulsby B; McGorry PD; Suzuki M; Kawasaki Y; Phillips LJ; Velakoulis D; Pantelis C
Arch Gen Psychiatry; 2009 Apr; 66(4):366-76. PubMed ID: 19349306
[TBL] [Abstract][Full Text] [Related]
15. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.
Ho BC; Andreasen NC; Nopoulos P; Arndt S; Magnotta V; Flaum M
Arch Gen Psychiatry; 2003 Jun; 60(6):585-94. PubMed ID: 12796222
[TBL] [Abstract][Full Text] [Related]
16. Association of IQ Changes and Progressive Brain Changes in Patients With Schizophrenia.
Kubota M; van Haren NE; Haijma SV; Schnack HG; Cahn W; Hulshoff Pol HE; Kahn RS
JAMA Psychiatry; 2015 Aug; 72(8):803-12. PubMed ID: 26083394
[TBL] [Abstract][Full Text] [Related]
17. Extensive gray matter volume reduction in treatment-resistant schizophrenia.
Anderson VM; Goldstein ME; Kydd RR; Russell BR
Int J Neuropsychopharmacol; 2015 Feb; 18(7):pyv016. PubMed ID: 25716781
[TBL] [Abstract][Full Text] [Related]
18. A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia.
Takahashi T; Suzuki M; Zhou SY; Tanino R; Nakamura K; Kawasaki Y; Seto H; Kurachi M
Schizophr Res; 2010 Jun; 119(1-3):65-74. PubMed ID: 20051316
[TBL] [Abstract][Full Text] [Related]
19. Focal gray matter density changes in schizophrenia.
Hulshoff Pol HE; Schnack HG; Mandl RC; van Haren NE; Koning H; Collins DL; Evans AC; Kahn RS
Arch Gen Psychiatry; 2001 Dec; 58(12):1118-25. PubMed ID: 11735840
[TBL] [Abstract][Full Text] [Related]
20. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment.
Ahmed M; Cannon DM; Scanlon C; Holleran L; Schmidt H; McFarland J; Langan C; McCarthy P; Barker GJ; Hallahan B; McDonald C
Neuropsychopharmacology; 2015 Sep; 40(10):2409-17. PubMed ID: 25829144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
